Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Patient characteristics

From: Osteopontin splice variants are differential predictors of breast cancer treatment responses

   n %
T 0 1 0.8
  1 59 49.6
  2 33 27.7
  3 6 5.0
  undefined 20 16.8
N 0 58 48.7
  1 14 11.8
  2 16 13.4
  3 11 9.2
  undefined 20 16.8
grade 1 36 30.3
  2 65 54.6
  3 18 15.1
Her2 low 69 58.0
  high 29 24.4
  undefined 21 17.6
PR - 64 53.8
  + 54 45.4
  undefined 1 0.8
ER - 59 49.6
  + 59 49.6
  undefined 1 0.8
BRCA-1 wild type 52 43.7
  mutant 26 21.8
  undefined 41 34.5
familial no 44 37.0
  yes 40 33.6
  undefined 35 29.4
chemotherapy AC 4 courses every 21 days, CMF 6 courses every 28 days 34 28.6
  CMF 6 courses every 28 days 55 46.2
  no 30 25.2
radiation therapy chest (50 Gy; Mon-Fri 2 Gy) 41 34.5
  chest/axilla (50 Gy; Mon-Fri 2 Gy) 31 26.1
  no 47 39.5
hormone treatment no 54 45.4
  tamoxifen 62 52.1
  1. The patient populations are described according to diverse clinical variables. CMF cyclophosphamide, methotrexate, fluorouracil, AC cyclophosphamide, doxorubicin